Prostate Cancer and Wnt/Stat3 Signaling

Prostate Cancer and Wnt/Stat3 Signaling Publisher

Etemad S¹ ; Manavi MS² ; Varnousafaderani MHH³ ; Faghihkhorasani F⁴ ; Ghaderi H⁵ ; Kordmahalleh SE⁶ ; Ebrahimi N⁷ ; Hajifatahaliha M⁸ ; Aref AR^{9, 10}

Show Affiliations

1. Department of Pathology, Faculty of Anatomical Pathology, Ghaem Hospital, University of Medicine, Mashhad, Iran
2. Otolaryngology Department, Tehran University of Medical Science, Tehran, Iran
3. Faculty of Medicine, University of Debrecen, Debrecen, Hungary
4. Xi'an Jiaotong University, Xi'an, China
5. Laboratory of Regenerative and Medical Innovation, Pasteur Institute of Iran, Tehran, Iran
6. School of Medicine, Guilan University of Medical Science, Rasht, Iran
7. Genetics Division, Department of Cell and Molecular Biology and Microbiology, Faculty of Science and Technology, University of Isfahan, Isfahan, Iran
8. Department of Immunology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran
9. Mass General Cancer Center, Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States
10. Broad Institute of MIT and Harvard, Harvard Medical School, Cambridge, MA, United States

Source: Prostate Cancer: Molecular Events and Therapeutic Modalities Published:2024

Abstract

Globally, prostate cancer remains a major health problem, needing a thorough knowledge of the underlying molecular processes that govern its develop ment. In this chapter, we dig into the complex functions of the Wnt and STAT3 signaling pathways in prostate cancer, illuminating their involvement in the pro gression and metastasis of the illness. The WNT and STAT3 signaling pathways are thoroughly discussed at the beginning of the chapter, emphasizing both their critical roles in healthy cellular activities and the dysregulation of these pathways in prostate cancer. Both routes are known to exert substantial influence on cellular growth, survival, migration, and differentiation during carcinogenesis. In addition, we investigate the crucial yet unresolved interaction among the WNT and STAT3 pathways in prostate cancer. Understanding the complex regulatory mechanisms driving prostate cancer growth may be revealed by examining the molecular and cellular interactions between different pathways. The potential of WNT and STAT3 as therapeutic targets in the treatment of prostate cancer is covered in great detail in this chapter. Targeting these pathways presents interesting opportunities for creating tailored therapeutics intended to slow disease progression and enhance patient outcomes due to their significant roles in tumor formation and metastasis. The importance of the WNT and STAT3 signaling pathways in prostate cancer and their value as possible therapeutic targets are highlighted in Chap. 6's conclusion. It may be possible to develop efficient precision medicines for patients with prostate cancer by better understanding their interactions and focusing on these pathways, thereby advancing oncology and enhancing clinical outcomes. © The Author(s). All rights reserved.

Related Docs

View other Related Docs

1. Stat3 Signaling in Prostate Cancer Progression and Therapy Resistance: An Oncogenic Pathway With Diverse Functions, Biomedicine and Pharmacotherapy (2023)

2. Resveratrol in Breast Cancer Treatment: From Cellular Effects to Molecular Mechanisms of Action, Cellular and Molecular Life Sciences (2022)

3. Targeting Autophagy in Prostate Cancer: Preclinical and Clinical Evidence for Therapeutic Response, Journal of Experimental and Clinical Cancer Research (2022)

4. The Role of Natural Products As Inhibitors of Jak/Stat Signaling Pathways in Glioblastoma Treatment, Oxidative Medicine and Cellular Longevity (2022)

5. Rewiring of Mirna-Mrna Bipartite Co-Expression Network As a Novel Way to Understand the Prostate Cancer Related Players, Systems Biology in Reproductive Medicine (2023)

6. Modulation of Cancer Cell Signaling by Long Noncoding Rnas, Journal of Cellular Biochemistry (2019)

7. The Importance of the Circrna/Wnt Axis in Gliomas: Biological Functions and Clinical Opportunities, Pathology Research and Practice (2024)

8. Prostate Cancer and Noncoding Rnas: A Focus on Mirnas, Lncrnas, and Circrnas, Prostate Cancer: Molecular Events and Therapeutic Modalities (2024)

Experts (# of related papers)

View all Related Experts

Laleh Sharifi (1)

Marjan Yaghmaie (1)

Style	Citing Format
MLA	Etemad S, et al.. "Prostate Cancer and Wnt/Stat3 Signaling." Prostate Cancer: Molecular Events and Therapeutic Modalities, vol. , no. , 2024, pp. 137-151.
APA	Etemad S, Manavi MS, Varnousafaderani MHH, Faghihkhorasani F, Ghaderi H, Kordmahalleh SE, Ebrahimi N, Hajifatahaliha M, Aref AR (2024). Prostate Cancer and Wnt/Stat3 Signaling. Prostate Cancer: Molecular Events and Therapeutic Modalities, (), 137-151.
Chicago	Etemad S, Manavi MS, Varnousafaderani MHH, Faghihkhorasani F, Ghaderi H, Kordmahalleh SE, Ebrahimi N, Hajifatahaliha M, Aref AR. "Prostate Cancer and Wnt/Stat3 Signaling." Prostate Cancer: Molecular Events and Therapeutic Modalities , no. (2024): 137-151.
Harvard	Etemad S et al. (2024) 'Prostate Cancer and Wnt/Stat3 Signaling', Prostate Cancer: Molecular Events and Therapeutic Modalities, (), pp. 137-151.
Vancouver	Etemad S, Manavi MS, Varnousafaderani MHH, Faghihkhorasani F, Ghaderi H, Kordmahalleh SE, et al.. Prostate Cancer and Wnt/Stat3 Signaling. Prostate Cancer: Molecular Events and Therapeutic Modalities. 2024;():137-151.
BibTex	@article{ author = {Etemad S and Manavi MS and Varnousafaderani MHH and Faghihkhorasani F and Ghaderi H and Kordmahalleh SE and Ebrahimi N and Hajifatahaliha M and Aref AR}, title = {Prostate Cancer and Wnt/Stat3 Signaling}, journal = {Prostate Cancer: Molecular Events and Therapeutic Modalities}, volume = {}, number = {}, pages = {137-151}, year = {2024} }
RIS	TY - JOUR AU - Etemad S AU - Manavi MS AU - Varnousafaderani MHH AU - Faghihkhorasani F AU - Ghaderi H AU - Kordmahalleh SE AU - Ebrahimi N AU - Hajifatahaliha M AU - Aref AR TI - Prostate Cancer and Wnt/Stat3 Signaling JO - Prostate Cancer: Molecular Events and Therapeutic Modalities VL - IS - SP - 137 EP - 151 PY - 2024 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract